What is Demyelination?

By , BSc

The term demyelination refers to loss of the myelin sheath that surrounds and protects axons in the central nervous system. Demyelination occurs as the result of diseases that damage the myelin sheath or the cells that form it. Diseases that are characterized by this loss of myelin are referred to as demyelinating diseases.

The myelin sheath covers and insulates axons, aiding the conduction of electrical signals between nerves. The process of demyelination disrupts this electrical nerve conduction, which leads to symptoms of neurodegeneration. Demyelination tends to be patchy and segmented, with various different areas being affected sequentially or simultaneously. Remyelination can also occur, with neural function being recovered through regeneration and repair. However, extensive loss of myelin generally leads to irreversible degeneration of the axon and cell body.

In the demyelination process, areas of lipid degeneration in the myelin sheath are referred to as neuritic plaques. These may be variable in size. The residual degenerated myelin sheath is removed by macrophages that gather at the affected site along with lymphocytes. As time progresses, the sites of demyelination become gray and hard (sclerotic) as the white matter is destroyed. Eventually the destruction of the myelin sheath is followed by direct damage to the axon or nerve fibre underneath.

Demyelinating diseases

Several conditions lead to demyelination and one of the most well known of the neurodegenerative disorders is multiple sclerosis. Here, the immune system targets the myelin sheath or the cells that form and maintain it. This disease is twice as common among women than among men and most people are aged between 15 and 55 years when the condition first presents. There have been cases of disease onset among individuals older and younger than this, but they are rare. The disease course in multiple sclerosis is usually relapsing and remitting, but it can also be progressive from disease onset or become progressive after periods of remission. The latent phase between initial symptom manifestation and the first relapse event is variable, but it may be a period of many years.

Examples of other demyelinating diseases include the following:

  • Transverse myelitis, where the spinal cord becomes inflamed
  • Optic neuritis, which refers to inflammation of the optic nerve
  • Acute disseminated encephalomyelitis, where the spinal cord and brain become inflamed
  • Neuromyelitis optica, where the central nervous system become inflamed and demyelinated, especially the brain and spinal cord
  • Adrenomyeloneuropathy or adrenoleukodystrophy, which are rare types of metabolic disorder


Demyelinating disease usually leads to muscle weakness and stiffness, loss of vision, sensation and coordination, pain and altered bowel and bladder function. A more comprehensive list of the symptoms and signs consistent with demyelinating diseases is given below.

Motor: Gait disturbance, weakness in the limbs/trunk, spasticity, difficulty with balance, hyperreflexia.

Visual: Diplopia (double vision), blurred vision, loss of vision and oscillopsia (oscillation of objects in the visual field).

Sensory: Parasthesia (tingling or pricking sensation), dysesthesia (abnormal, unpleasant sense of touch), numbness, Lhermitte’s sign (electrical sensation in the back), MS hug (pain in the torso area), trigeminal neuralgia (severe facial pain), hyperpathia (raised sensitivity and threshold to pain), allodynia (pain from non-painful stimuli) and propioception deficit (abnormal movement due to abnormal perception).

Cerebellar: Ataxia (poor coordination and balance), tremor, incoordination.

Genitourinary: Constipation, impotence, frequently occurring urinary tract infection, incontinence, urinary urgency/retention/frequency, anorgasmia and dyspareunia (pain during sex).

Neuropsychiatric: Anxiety, depression, irritability, impaired attention, concentration and memory.

Factors that are thought to increase the risk of demyelinating disease include infection, autoimmune disorder, genetic predisposition and exposure to toxins. Research has also shown that exposure to weed killers and insecticides containing organophosphates can cause demyelination. In addition, neuroleptic agents used in the treatment of psychosis have been shown to cause demyelination.


There is no cure for demyelinating diseases or to prevent their progression, but early treatment can help to minimize the effects of attacks, manage symptoms and modify disease course. Depending on the specific disorders a range of therapies are available and may include drugs that can reduce the frequency of new lesions forming. Approaches to managing symptoms include muscle relaxants, physiotherapy and drugs to alleviate fatigue and pain.

Further Reading

    Last Updated: Jul 20, 2015

    Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
    The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
    Post a new comment